Shopping Cart
Remove All
Your shopping cart is currently empty
DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones), aimed at reducing or preventing acquired chemotherapy resistance by inhibiting intracellular copper chaperones. It binds to Atox1 and CCS, thereby reducing cancer cell proliferation and tumor growth.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $42 | In Stock | In Stock | |
| 5 mg | $68 | In Stock | In Stock | |
| 10 mg | $105 | In Stock | In Stock | |
| 25 mg | $198 | In Stock | In Stock | |
| 50 mg | $312 | In Stock | In Stock | |
| 100 mg | $468 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $75 | In Stock | In Stock |
| Description | DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones), aimed at reducing or preventing acquired chemotherapy resistance by inhibiting intracellular copper chaperones. It binds to Atox1 and CCS, thereby reducing cancer cell proliferation and tumor growth. |
| In vitro | DC_AC50 synergised with carboplatin in combination treatment of human and canine OSA cells to reduce cancer cell viability.?DC_AC50-treated cells were significantly less mitotically active, as demonstrated by decreased expression of phospho-histone H3 and cell cycle analysis.?DC_AC50 also potentiated carboplatin-induced apoptosis in OSA cells and decreased clonogenic survival.?Finally, DC_AC50 reduced the migratory ability of OSA cells.?These results justify further investigation into inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance. |
| Molecular Weight | 424.26 |
| Formula | C17H12BrF2N3OS |
| Cas No. | 497061-48-0 |
| Smiles | Nc1c(sc2nc3CCCc3cc12)C(=O)Nc1c(F)cc(F)cc1Br |
| Relative Density. | 1.759 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (58.93 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.